Increased Th17 cells contribute to disease progression in patients with HBV-associated liver cirrhosis

Journal of Viral Hepatitis

Volumn 19, Issue 6, 2012, Pages 396-403

  Sun, H Q ^a   Zhang, J Y ^b   Zhang, H ^c   Zou, Z S ^b   Wang, F S ^b   Jia, J H ^a  

^a SHANDONG UNIVERSITY   (China)

^b BEIJING 302 HOSPITAL   (China)

^c SHANDONG AGRICULTURAL UNIVERSITY   (China)

Author keywords

fibrosis; hepatitis B; inflammation; liver cirrhosis; Th17 cells

Indexed keywords

CYTOKINE; INTERLEUKIN 17 RECEPTOR; RECOMBINANT INTERLEUKIN 17; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INFLAMMATION; LIVER; LIVER BIOPSY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STELLATE CELL; TH17 CELL;

ADULT; AGED; BIOPSY; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HEPATITIS B, CHRONIC; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-17; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-17; SEVERITY OF ILLNESS INDEX; TH17 CELLS; YOUNG ADULT;

EID: 84861100073     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01561.x     Document Type: Article

References (33)

1. Hernandez-Gea V, Friedman SL,. Pathogenesis of liver fibrosis. Annu Rev Pathol 2011; 6: 425-456.
2. Friedman SL,. Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol 2010; 27: 425-436.
3. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-649.
4. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-470. (Pubitemid 32119037)
5. Rehermann B, Nascimbeni M,. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215-229. (Pubitemid 40364823)
6. Lim YS, Kim WR,. The global impact of hepatic fibrosis and end-stage liver disease. Clin Liver Dis 2008; 12: 733-746 vii.
7. Wang FS,. Clinical immune characterization of hepatitis B virus infection and implications for immune intervention: progress and challenges. Hepatol Res 2007; 37: S339-S346.
8. Wang FS, Zhang Z,. Host immunity influences disease progression and antiviral efficacy in humans infected with hepatitis B virus. Expert Rev Gastroenterol Hepatol 2009; 3: 499-512.
9. Zhang JY, Zou ZS, Huang A, et al. Hyper-activated pro-inflammatory CD16 + monocytes correlate with the severity of liver injury and fibrosis in patients with chronic hepatitis B. PLoS ONE 2011; 6 (3): e17484.
10. Safadi R, Ohta M, Alvarez CE, et al. Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology 2004; 127: 870-882. (Pubitemid 39208419)
11. Wynn TA,. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004; 4: 583-594.
12. Radaeva S, Sun R, Jaruga B, et al. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 2006; 130: 435-452. (Pubitemid 43202042)
13. Park O, Jeong WI, Wang L, et al. Diverse roles of invariant natural killer T cells in liver injury and fibrosis induced by carbon tetrachloride. Hepatology 2009; 49: 1683-1694.
14. Novobrantseva TI, Majeau GR, Amatucci A, et al. Attenuated liver fibrosis in the absence of B cells. J Clin Invest 2005; 115: 3072-3082. (Pubitemid 41567572)
15. Connolly MK, Bedrosian AS, Mallen-St Clair J, et al. In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-alpha. J Clin Invest 2009; 119: 3213-3225.
16. Iredale JP,. Hepatic stellate cell behavior during resolution of liver injury. Semin Liver Dis 2001; 21: 427-436. (Pubitemid 32923770)
17. Melhem A, Muhanna N, Bishara A, et al. Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J Hepatol 2006; 45: 60-71. (Pubitemid 43850614)
18. Muhanna N, Doron S, Wald O, et al. Activation of hepatic stellate cells after phagocytosis of lymphocytes: a novel pathway of fibrogenesis. Hepatology 2008; 48: 963-977.
19. Muhanna N, Abu Tair L, Doron S, et al. Amelioration of hepatic fibrosis by NK cell activation. Gut 2011; 60: 90-98.
20. Weaver CT, Hatton RD, Mangan PR, et al. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007; 25: 821-852. (Pubitemid 46697925)
21. Lemmers A, Moreno C, Gustot T, et al. The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology 2008; 49: 646-657.
22. + T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology 2010; 51: 81-91.
23. O'Quinn DB, Palmer MT, Lee YK, et al. Emergence of the Th17 pathway and its role in host defense. Adv Immunol 2008; 99: 115-163.
24. Yasumi Y, Takikawa Y, Endo R, et al. Interleukin-17 as a new marker of severity of acute hepatic injury. Hepatol Res 2007; 37: 248-254. (Pubitemid 46505838)
25. Wang L, Chen S, Xu K, et al. IL-17 expression is correlated with hepatitis B related liver diseases and fibrosis. Int J Mol Med 2011; 27: 385-392.
26. Mookerjee RP, Stadlbauer V, Lidder S, et al. Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. Hepatology 2007; 46: 831-840. (Pubitemid 47436130)
27. Tritto G, Bechlis Z, Stadlbauer V, et al. Evidence of neutrophil functional defect despite inflammation in stable cirrhosis. J Hepatol 2011; 55: 574-581.
28. Scheuer PJ,. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-374.
29. Xu L, Hui AY, Albanis E, et al. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 2005; 54: 142-151. (Pubitemid 40007234)
30. Zhang Z, Zou ZS, Fu JL, et al. Severe dendritic cell perturbation is actively involved in the pathogenesis of acute-on-chronic hepatitis B liver failure. J Hepatol 2008; 49: 396-406.
31. + regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006; 177: 739-747. (Pubitemid 43939189)
32. Zhang JY, Song CH, Shi F, et al. Decreased ratio of Treg cells to Th17 cells correlates with HBV DNA suppression in chronic hepatitis B patients undergoing entecavir treatment. PLoS ONE 2010; 5: e13869.
33. Zhang Z, Zhang JY, Wherry EJ, et al. Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B. Gastroenterology 2008; 134: 1938-1949.